CRSDA: A Potential Drug Target for Cancer (G3590)
CRSDA: A Potential Drug Target for Cancer
The immune system is a critical component of the body that defends against harmful pathogens and maintains overall health. One of the key proteins involved in this process is Interleukin-11 (IL-11), which is a cytokine that plays a crucial role in the regulation of immune responses and inflammation. However, in some diseases, such as cancer, IL-11 can be overexpressed or underexpressed, leading to abnormal immune responses that contribute to disease progression.
One potential drug target for IL-11 is CRSDA (Cytotoxic Tissue Response associated withApoptosis), which is a protein that is expressed in a variety of tissues and cells in the body, including immune cells, neurons, and epithelial cells. CRSDA has been shown to play a role in the regulation of apoptosis, which is the process by which cells undergo programmed cell death.
CRSDA is also known as PD-L1, which stands for Programmed Cell Death-Ligand 1. This protein is a negative regulator of thePD-L1/PD-L1R signaling pathway, which is a critical pathway that regulates the balance between T cell activation and apoptosis. In T cells, PD-L1 helps to ensure that T cells are able to recognize and respond to antigens, while PD-L1R helps to ensure that T cells are able to induce apoptosis when they are no longer needed.
The Role of CRSDA in Cancer
One of the key ways that CRSDA is involved in cancer is by contributing to the development and progression of cancer stem cells (CSCs). CSCs are a type of cell that have the ability to self-replify and can give rise to all of the different types of cancer cells that can form from a primary tumor. In cancer, CSCs can evade the immune system and continue to divide and proliferate, leading to the development of a cancer stem cell niche.
One of the ways that CRSDA contributes to the development of CSCs is by regulating the apoptosis that occurs in response to DNA damage or other forms of stress. When cells are exposed to stressors, such as DNA damage or oncogenic signaling, CRSDA helps to ensure that they undergo apoptosis in a timely manner. This is important because if cells are able to survive in the face of stress, they have a higher chance of developing into cancer stem cells.
Another way that CRSDA contributes to the development of cancer is by promoting the maintenance of a survival signaling loop between oncogenic signaling and DNA damage. Oncogenic signaling pathways, such as the PI3K/Akt signaling pathway, are often involved in the regulation of cell survival and growth, and are often disrupted in cancer. However, these pathways can also contribute to the development of DNA damage, which can then be used by CRSDA to promote apoptosis.
The Potential therapeutic Benefits of CRSDA
The overexpression of CRSDA has been shown to contribute to the development and progression of a variety of diseases, including cancer. By targeting CRSDA as a drug target, researchers have been able to demonstrate the potential therapeutic benefits of CRSDA in a variety of settings.
One of the key benefits of CRSDA as a drug target is its ability to inhibit the development of cancer stem cells. By inhibiting the activity of CRSDA, researchers have been able to reduce the number of cancer stem cells that have been generated from a primary tumor. This has the potential to lead to a reduction in the number of tumors that are able to spread and develop into invasive diseases.
Another benefit of CRSDA as a drug target is its ability to
Protein Name: Interleukin 11 Receptor Subunit Alpha
Functions: Receptor for interleukin-11 (IL11). The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells (Probable). Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number
The "IL11RA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL11RA comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
IL12A | IL12A-AS1 | IL12B | IL12RB1 | IL12RB2 | IL13 | IL13RA1 | IL13RA2 | IL15 | IL15RA | IL16 | IL17A | IL17B | IL17C | IL17D | IL17F | IL17RA | IL17RB | IL17RC | IL17RD | IL17RE | IL17REL | IL18 | IL18BP | IL18R1 | IL18RAP | IL19 | IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3)
